Fritz Kunz, a veteran Swiss pharmaceutical company executive, has joined the board of directors of the Geneva-based, PregLem, a biopharmaceutical company specializing in reproductive medicine. Dr Kunz was most recently chairman of the board of Speedel, which is being acquired by Novartis.
A chemist by training, Dr Kunz worked for two decades at Sandoz, which is now part of Novartis. In 2007, he became chairman of the board of Kuros Biosurgery, a private Swiss biomedical company which develops injectable materials for localized therapies.
Founded in 2006, PregLem develops compounds for the treatment of major benign gynecological conditions as well as infertility.
Copyright 2008 Evernow Publishing Ltd